Home  |  Media  |  Papers & Publications  |  Mailing List  |  News  |  Contact Me                                                                          Bookmark This Page
Dr. Steven Treon
Dr. Treon is listed by US News & World Report as being in the top 1% of all doctors in the United States for his specialty.


Please visit our main program website: Bing Center for Waldenstrom's Macroglobulinemia. This site contains information on the latest treatment recommendations, abstracts, news and events, current and pending clinical trials and participating institutions, basic research, and publications, as well as photos and brief bios of the Bing Center staff.


WM Workshops: Starting with the first International Workshop for WM in Washington DC in Sept. 2000, worshops have been held bi-annually, the most recent in October, 2018 in New York, NY. These workshops provide a venue for the WM scientific community to collaborate and share their latest research with the goal of advancing the knowledge of the genetic basis and pathogenesis of WM, and the development of theraputics for this malignancy. To learn more, please visit our WM Workshop Website.


Patient/Physician Summits: Starting with the first summit in Boston in November, 2001, these conferences have provided a valuable opportunity for patients, their families and caregivers to meet face-to-face with the leaders of the WM scientific community. They can learn the latest developments in the research and treatment of WM, and also participate in working sessions and panel discussions. To learn more, please visit our WM Summit Website.


WM Clinical Trials Group: To find a WM specialist in your area, including information on clinical trials involving WM, please visit our WM Clinical Trials Group Website.

MYD88 L265P is a commonly recurring mutation in patients with Waldenström’s macroglobulinemia that can be useful in differentiating Waldenström’s macroglobulinemia and non-IgM LPL from B-cell disorders that have some of the same features. Click the graphic to download this groundbreaking NEJM publication.


This book sheds new light on clinical, biological and therapeutic data on the rare disease Waldenström’s Macroglobulinemia (WM) with the participation of widely-recognized experts, involved in this field. It represents the efforts of physicians, scientists and patients, all around the world, to better understand and cure this rare disease.


Dedicated to the Discovery of the Cause and Cure of Waldenstrom's Macroglobulinemia

Dr. Steven Treon is the Director of the Bing Center for Waldenström's Macroglobulinemia and an Attending Physician for the Department of Medical Oncology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston, Massachusetts. He is also a Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group.

Dr. Treon received a medical degree with honors from the Boston University School of Medicine, and a master’s degree in biochemistry and a doctorate of philosophy in tumor immunology from the graduate school at Boston University Medical Center. Dr Treon completed an internship and residency in internal medicine at Boston University Medical Center. He also completed a clinical fellowship in hematology and oncology at the Massachusetts General Hospital and a research fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. He received certification from the American Board of Internal Medicine (ABIM) in Internal Medicine and Medical Oncology, and continues to maintain his ABIM certification in Medical Oncology.

Dr. Treon’s research interests are focused on understanding the genetic basis and pathogenesis of Waldenström’s Macroglobulinemia (WM), and the development of targeted therapeutics for this malignancy. Using whole genome sequencing, the Treon laboratory discovered the highly prevalent MYD88 L265P and CXCR4 WHIM mutations in WM, permitting the development of diagnostic molecular testing and targeted treatments for WM. Signaling work performed in the Treon laboratory established the critical role of Bruton’s Tyrosine Kinase (BTK) as a key mediator of MYD88 signaling in WM cells. This discovery enabled the first ever breakthrough designation by the U.S. FDA for the accelerated approval of the BTK inhibitor ibrutinib for the treatment of WM. Dr. Treon served as the principal investigator of the pivotal trial that supported the regulatory approval of ibrutinib by the U.S. FDA and European Medicines Agency for the treatment of WM. He has also been the principal investigator for other clinical trials that resulted in the adoption of many novel therapeutics and combination therapies for the treatment of WM.

Dr. Treon has published over 250 original articles, reviews, reports, and book chapters that have appeared in many high impact journals and text books. He has been a keynote speaker and lecturer on the genomic basis, pathogenesis, clinical features, and treatment of WM at prestigious national congresses, international conferences, hospital grand rounds, tumor boards, regional medical society conferences, workshops, and patient meetings. He is a member of the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research, European Society of Hematology, and the British Society of Hematology, and has given “Meet the Professor”, Educational Session, as well as presentations on original research at the annual meetings of these associations. Dr. Treon is also the principal organizer of the International Workshops on WM which have served as the principal forum for the exchange of novel scientific and clinical data on WM. He has been a mentor to physicians and scientists at the Bing Center for WM, and is also a regular lecturer at Harvard Medical School and its affiliated hospitals where he teaches medical students, interns, residents and fellows on the topic of plasma cell malignancies.

For his clinical and research efforts, Dr. Treon has received awards from various organizations including an ASCO Young Investigator Award, the Robert A. Kyle Award, the Jan Gosta Waldenstrom Lifetime Achievement Award, the Laurie Strauss Leukemia Society Outstanding Cancer Investigator Award, designation as “America’s Top Doctor” by U.S. News and World Report, and the “One-Hundred Award” from the Massachusetts General Hospital. In 2011, and 2013, Dr. Treon’s research work received “Best of ASH” designations at the Annual Meeting of the American Society of Hematology.

Click here to download Dr. Treon's biosketch

Featured News Items

The 10th International Workshop for Waldenstrom's Macroglobulinemia was held from October 11th through the 13th, 2018 in New york City. The venue chosen for this meeting is one of New York City’s premier hotels, the New York Marriott Downtown Hotel and Conference center, situated in Lower Manhattan near Battery Park. The hotel nestles in one of the city’s most historic areas near Wall Street, the 9/11 Memorial Museum and One World Observatory. Onsite registration and check-in began at 12:00 on Wednesday, October 10th, conference sessions starting on Thursday, the 11th, at 7:30am. Overall, IWWM-10 included 16 sessions with 73 technical presentations including a Junior Investigator Poster presentation event with 5 short oral presentations, 79 WM-related posters, 8 "Keynote" lectures, Opening and Closing Ceremonies with associated award presentations, a Faculty Reception, 5 panel discussions on treatment approaches to WM, and 3 consensus panel discussions. For more information, please visit http://wmworkshop.org/conferences/new-york-2018

New Approaches to Treating Waldenström's Macroglobulinemia

At the October, 2019 Lymphoma & Myeloma Congress, Dr. Steven Treon provided an update on the latest research in the treatment of Waldenström Macroglobulinemia.

For the past 18 years, the Lymphoma & Myeloma congress has been recognized around the world as the most respected forum for industry-leading hematologic research —it’s where interdisciplinary specialists convene to explore the controversial and the complex, the emerging and the exciting, and discuss, debate, and discover along the way.